Carisma Therapeutics, Inc.
CARM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 31.6% | 51.7% | -63% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -204% | -396.8% | 100% | 99.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -289.5% | -575.7% | -571.4% | -32.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -308.1% | -582.3% | -622.6% | -1.3% |
| EPS Diluted | -1.46 | -2.59 | -1.52 | -1.01 |
| % Growth | 43.6% | -70.4% | -50.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |